Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 6

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Bonomarlot® which was manifested in a decrease in weakness, rapid fatigue, general malaise, and shortness of breath after light or moderate physical activity. The drug’s effect also decreased palpitations, headaches, tinnitus, sleep disturbances, appetite, and increased concentration and performance (Table 1). It is important to note that the improvement in the condition of patients of the primary group occurred in a shorter time than in the control group, which used only conventional therapy. If in the patients of the control group, the improvement in the condition occurred on average after 35.6 ± 2.7 days, then in the patients of the primary group - after 26.2 ± 1.6 days. Thus, the time of improvement in patients with anemia with the use of BONOMARLOT®, in addition to conventional therapy, was reduced by 24.4%. Dynamics of subjective indicators in patients with anemia Table 1 Indicator Number of patients, % Before treatment After treatment with After treatment with conventional therapy (control BONOMARLOT® (primary group) group) Weakness 96,0 58,2* 25,4*# Shortness of breath 78,2 48,5* 21,3*# Rapid fatigability 82,2 63,2* 29,5*# Reduced performance 92,4 67,3* 34,7*# Tinnitus 74,1 42,1* 23,1*# Decreased concentration of attention 89,5 57,5* 34,1*# Headaches 68,4 41,8* 26,4*# Palpitations 65,9 38,3* 21,7*# Sleep disturbances 77,6 47,3* 29,1*# * p <0.05 reliable in comparison with the indicator in patients before treatment; # p <0.05 reliable in comparison with the indicator in patients after treatment with conventional means. Effect of BONOMARLOT® on the content of erythrocytes and hemoglobin in the Table 2 blood serum of patients with anemia Indicator Norm Before After treatment with After treatment with treatment conventional therapy BONOMARLOT® (control group) (primary group) Erythrocytes, (×10 12/l) 3,7-4,7 3,3±0,7 3,6±0,4 3,7±0,5 Hemoglobin, (g/l) 115-145 77,8±2,8 95,4±3,2* 112,6±4,2*# * p <0.05 –reliable in comparison with the indicator in patients of the control group. # p <0.05 –reliable in comparison with the indicator in patients of the control group. In the laboratory study, after the use of BONOMARLOT®, a significant improvement in the parameters of the content of erythrocytes and hemoglobin in the blood was noted. As expected, it was more pronounced than the indicators in the patients of the control group (Table 2). The noted changes in the parameters in the peripheral blood of patients while taking BONOMARLOT® correlate with clinical indicators. They indicate the restoration of an adequate response of the body’s hematopoietic system in response to malnutrition. Analysis of the data allows us to conclude that BONOMARLOT® has a normalizing effect on cellular

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.